DAPA ACT HF-TIMI 68

DAPA ACT HF-TIMI 68

This study is designed to assess the effect of in-hospital initiation of dapagliflozin, as compared with placebo, on the clinical outcome of cardiovascular death or worsening heart failure in patients with heart failure with reduced ejection fraction who have been stabilized during hospitalization for acute heart failure.

Please use this link for further information:

Primary Investigator: Gregory Egnaczyk